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A B S T R A C T
Currently, there are no licensed human vaccines or antivirals for treatment of or prevention from infection with
encephalitic alphaviruses. Because epidemics are sporadic and unpredictable, and endemic disease is common
but rarely diagnosed, it is difficult to identify all populations requiring vaccination; thus, an effective post-
exposure treatment method is needed to interrupt ongoing outbreaks. To address this public health need, we
have continued development of ML336 to deliver a molecule with prophylactic and therapeutic potential that
could be relevant for use in natural epidemics or deliberate release scenario for Venezuelan equine encephalitis
virus (VEEV). We report findings from in vitro assessments of four analogs of ML336, and in vivo screening of
three of these new derivatives, BDGR-4, BDGR-69 and BDGR-70. The optimal dosing for maximal protection was
observed at 12.5 mg/kg/day, twice daily for 8 days. BDGR-4 was tested further for prophylactic and therapeutic
efficacy in mice challenged with VEEV Trinidad Donkey (TrD). Mice challenged with VEEV TrD showed 100%
and 90% protection from lethal disease when treated at 24 and 48 h post-infection, respectively. We also
measured 90% protection for BDGR-4 in mice challenged with Eastern equine encephalitis virus. In additional
assessments of BDGR-4 in mice alone, we observed no appreciable toxicity as evaluated by clinical chemistry
indicators up to a dose of 25mg/kg/day over 4 days. In these same mice, we observed no induction of interferon.
Lastly, the resistance of VEEV to BDGR-4 was evaluated by next-generation sequencing which revealed specific
mutations in nsP4, the viral polymerase.
1. Introduction
Viruses in the family, Togaviridae, genus, Alphavirus, cause illness
that may progress to encephalomyelitis in humans (Calisher, 1994;
Knipe and Howley, 2013; Weaver et al., 2012). These viruses include
Venezuelan (VEEV), Eastern (EEEV) and Western equine encephalitis
viruses (WEEV). These viruses have been recognized since the 1930's
when they were associated with outbreaks in the North and South
America in horses and humans. The recognition of disease in humans
often follows an epizootic course in domestic or wild animals. VEEV has
been known to affect hundreds of thousands of people in the Americas
over the past century. An estimated 70,000–100,000 humans, and si-
milar numbers of equines, infected with VEEV were reported during the
last outbreak in 1995, including hundreds of fatalities and still-births
along with thousands of survivors with neurologic sequelae (Rivas
et al., 1997). Serious human disease associated with EEEV is primarily
associated with isolates circulating in North America although more
recently cases have been reported in Latin America (Carrera et al.,
2013; Sabattini et al., 1991). CDC estimates that only 4–5% of human
EEEV infections lead to clinical disease resulting in approximately
seven human cases of EEEV each year of which approximately 41% are
fatal (Lindsey et al., 2018). Most of the cases show neuroinvasive
https://doi.org/10.1016/j.antiviral.2019.04.004
Received 18 January 2019; Received in revised form 30 March 2019; Accepted 3 April 2019
∗ Corresponding author.
∗∗ Corresponding author.
E-mail addresses: cjonsson@uthsc.edu (C.B. Jonsson), jennifer.golden@wisc.edu (J.E. Golden).
Antiviral Research 167 (2019) 25–34
Available online 07 April 2019
0166-3542/ © 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license 
(http://creativecommons.org/licenses/BY-NC-ND/4.0/).
T
disease and occur in the eastern part of the US. Physical and mental
sequelae are prominent in EEE survivors and range from minimal brain
dysfunction to severe intellectual impairment, personality disorders,
seizures, paralysis, and cranial nerve dysfunction.
Currently, there are no licensed vaccines or antivirals for treatment
or prevention of V/E/WEEV infection and disease. Because epidemics of
V/E/WEEV are sporadic and unpredictable, and endemic disease is
common (estimated 10,000 cases annually in the Americas) but rarely
diagnosed (Aguilar et al., 2011), it is difficult to identify all populations
requiring vaccination; thus, an effective post-exposure treatment
method is needed to interrupt ongoing outbreaks. To address this public
health need, we have been active in the development of novel small
molecule antivirals that could be relevant for use both in natural epi-
demics of New World alphaviruses as well as a deliberate release sce-
nario (Chung et al., 2010, 2014, 2016).
ML336 is a benzamidine that emerged as part of a medicinal
chemistry campaign focused on VEEV antivirals (Schroeder et al.,
2014). ML336 analogs were prepared to better understand the struc-
ture-activity and structure-property relationships associated with the
chemical series. Herein we report the evaluation of BDGR-4 and other
new derivatives of ML336 (Schroeder et al., 2014) for inhibitory ac-
tivity against wild type strains of VEEV and EEEV in vitro and in vivo.
Of the new derivatives advanced for animal studies, BDGR-4 shows
excellent efficacy for therapeutic and prophylactic treatment of VEEV
and prophylactic treatment of EEEV in mice.
2. Material and methods
2.1. Cells and viruses
EEEV (strain FL93-939) was obtained from WRCEVA (Galveston,
TX), VEEV strain Trinidad Donkey (TrD) came from BEI (item #: NR-
332) and VEEV TC-83 (lyophilized vaccine) was a gift from Dr. Connie
Schmaljohn (United States Army Medical Research Institute of
Infectious Diseases, MD). WEEV (strain California) was obtained from
ATCC (VR-70). Virus seed stocks were amplified in Vero76 cells or BHK-
21 in Dulbecco's modified essential media (DMEM) or Minimum
Essential Media with Earle's modification (MEM-E) with 10% fetal bo-
vine serum (FBS) and clarified by low speed centrifugation. For studies
in mice, seed stock virus as diluted to a concentration of
3.33×108 pfu/ml (1×107 pfu/0.03ml) in Phosphate Buffered Saline
PBS (HyClone).
2.2. Chemistry
Syntheses of ML336 and BDGR-4 have been previously described
(Schroeder et al., 2014). Previously undescribed analogs used in this
work include BDGR-5, BDGR-69 and BDGR-70, the syntheses and
characterization of which are included in the supplementary informa-
tion. All final compounds were purified after synthesis, characterized by
1H and 13C NMR, high-resolution mass spectroscopy, and analyzed for
purity by UV-LCMS (> 95%). Chiral compounds were analyzed by
chiral HPLC to determine enantiomeric excess.
2.3. In vitro antiviral assays
The 50% effective concentration (EC50), titer-reduction activity, and
cytotoxicity were measured as described previously (Chung et al.,
2014). Briefly, measurement of the EC50 used Vero 76 cells that were
seeded and cultured in white, solid, 96-well plates overnight. The
compounds were diluted in cell culture media (2-fold, 8 points, serially
diluted) was added to each well. Two hours later, the cells were in-
fected with virus at an MOI of 0.05. The infected plates were incubated
for 48 h and the cell viability, protected from virus-induced cytopathic
effect, was measured with Cell Titer-Glo (Promega). All experiments
were replicated in three plates and EC50 were calculated from
normalized cell viability values from the replicate data using XLfit
software (IBDS) with Module 204, 4-parameter logistic model. Cyto-
toxicity was conducted in parallel with cell culture media in place of
virus.
For titer reduction assays, Vero76 cells were grown in 12-well plates
overnight and then infected with virus at a MOI of 0.05 diluted in MEM-
E, 10% FBS, l-glutamine, and 12.5mM HEPES. After one hour of ad-
sorption on ice, cells were washed with PBS twice and media containing
5 μM of compound was added to each well. After an 18 h of incubation
in an incubator at 37 °C with 5% CO2, the cell culture supernatant was
removed and stored at −80 °C. Virus titer was determined by with a
virus infection center assay as previously described (Adcock et al.,
2017). Briefly, we made serial dilutions of supernatant taken from
treatments and infected confluent Vero76 cells grown in 24-well plates.
We added a semisolid overlay media (cell culture media with 0.75%
methylcellulose). Virus infection centers were visualized with 0.2%
crystal violet in 4% paraformaldehyde and 10% ethanol.
Virus titers in brain were measured by plaque assay or 50% tissue
culture infectious dose (TCID50) assay. Briefly, brain was homogenized
with tissue homogenizer (Omni International) on ice in the virus culture
media (EMEM supplemented with 2% of heat-inactivated FBS, 2mM L-
glutamine, and 1% penicillin/streptomycin) to be 10% w/v, cen-
trifuged, and then kept clarified supernatant at −80C freezer until use.
For plaque assay, upon reaching more than 90% confluence of Vero
76 cells grown overnight on 6 well tissue culture plates, growth media
was removed and 100 μl of 10-fold virus dilutions from 101 to 108 were
added in a duplicate format and incubated for 1 h, with rocking every
15min to allow virus adsorption. After 1 h adsorption, cells were wa-
shed twice with DPBS, and 2ml overlay consisting 1.2% Avicel in virus
culture media was added, and the plates were incubated at 37 °C for
72 h. After incubation, cells were fixed for 15min by adding 1ml of
10% buffered formalin and then removed overlay in a waste container.
Fixed cells were stained with 0.2% crystal violet for 15min. For the
TCID50 assay, cells were grown to more than 90% confluence of Vero
76 cells in 96 well tissue culture plates, growth media was removed and
100 μl of 10-fold virus dilutions from 101 to 108 in the virus culture
media were added in a quadruplicate format. After 72 h incubation,
infected cells were observed for CPE under the 40× microscope fol-
lowed by performing MTS based cell viability assay (Promega) ac-
cording to manufacturer's guidance. TCID50 titers were decided by the
method of Reed and Muench (1938).
EEEV titers in tissues or plasma were assayed using an infectious cell
culture assay where a specific volume of either tissue homogenate or
serum was added to the first tube of a series of dilution tubes. Serial
dilutions were made and added to Vero cells. Three days later cyto-
pathic effect (CPE) was used to identify the end-point of infection. Four
replicates were used to calculate the 50% cell culture infectious doses
(CCID50) per mL of plasma or gram of tissues.
2.4. Mouse efficacy studies
All groups of mice were randomly assigned to experimental groups
and marked with ear tags. In all studies, mice were monitored for
mortality and disease signs until 21 days post-virus inoculation (dpi).
Individual weights were recorded daily 0–7 dpi. The VEEV studies
conducted at the University of Louisville were conducted in accordance
with the approval of the Institutional Animal Care and Use Committee
(IACUC) protocol #16644. The EEEV study conducted at Utah State
University (USU) was conducted in accordance with the approval of the
IACUC of USU (Protocol #10081). The work was done in the AAALAC-
accredited USTAR Laboratory facility of USU. The National Institutes of
Health approval for USU and UofL are PHS Assurance no. D16-00468
and PHS Assurance no. A3586-01 in accordance with the National
Institutes of Health Guide for the Care and Use of Laboratory Animals
(https://olaw.nih.gov/policies-laws/phs-policy.htm, 2015).
TC-83 Screening. The in vivo efficacy of BDGR-4, 69 and 70
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compounds were screened at 25mg/kg/day in approximately 5-6-
week-old C3H/HeN mice (Charles River) by challenge with 1× 107 pfu
VEEV TC-83. Compounds were formulated in 21.4% PEG400/8.6%
Kolliphor RH40/70% Water. On day 0, mice were given the first dose
via intraperitoneal (IP) injection approximately 2 h before intranasal
(IN) virus challenge. A second dose was administered approximately 6 h
post-challenge. Dosing continued twice daily (BID, 12 h) for five days.
Virus titers in mouse brains were measured using TCID50 or plaque
assay as described above.
TrD Screening. The in vivo efficacy of BDGR-4 and ML336 com-
pounds were screened with 25mg/kg/day in 5-6-week-old BALB/c
mice (Charles River) by challenge with VEEV TrD administered by the
subcutaneous route. Dosing by IP occurred every 12 h for 8 days
starting on Day 0. The first dose was administered at 2 h prior to virus
challenge. On Day 4 following virus challenge, a subset of mice from
each group were humanely euthanized via CO2 asphyxiation followed
by cervical dislocation. The brain from each mouse was collected,
placed into individual pre-labeled tubes, and snap frozen in liquid ni-
trogen. Virus titers in mouse brains were measured using TCID50 or
plaque assay as described above.
EEEV screening. C57BL/6 mice, supplied by Jackson Laboratories,
were used. Mice (n=15) were administered initial doses of BDGR-4 at
2 h prior to virus challenge via i.p. injection in a volume of 0.1mL. Mice
were challenged with 104.3 CCID50/0.2 ml EEEV strain FL93-939,
which was administered via bilateral s.c. injection (0.1 mL per injec-
tion) in the inguinal fold on each side of the abdomen. Placebo, sham,
and untreated and uninfected normal control groups were included in
this study. Compounds were provided in powder form and were diluted
to the appropriate concentration in 25% Kollisolv PEG400, 10%
Kolliphor RH40 and 65% water with intermediate vortexing. Mice were
treated with BDGR-4 twice daily for 8 days. On 6 dpi, 5 mice from
groups treated with the highest doses of BDGR-4 or placebo, as well as
from the placebo-treated, sham-infected group were necropsied and
brain tissues were collected for virus titration via infectious cell culture
assay. Serum was collected from all surviving mice on 21 dpi for as-
sessment of neutralizing antibodies by PRNT assay.
2.5. Quantification of neutralizing antibody in EEEV-infected mice
Neutralizing antibody was quantified using a 50% plaque reduction
neutralization titer (PRNT50) assay. Serum samples were heat in-
activated at 56 °C for 30min in a water bath. One half serial dilutions,
starting at a 1/10 dilution, of test sera were made. Dilutions were then
mixed 1:1 with an appropriate titer of EEEV in MEM containing 2%
fetal bovine serum (FBS) and incubated at 4 °C overnight. The virus-
serum mixture was then added to individual wells of a 12-well tissue
culture plate with Vero76 cells (4× 105 cells/well). Viral adsorption
proceeded for one hour at 37 °C and 5% CO2, followed by addition of
1.7% (4000cps) methylcellulose overlay medium containing 10% FBS
to each well. Plates were incubated for 4 days, then stained with crystal
violet (with 1% (wt/vol) crystal violet in 10% (vol/vol) ethanol) for
20min. The reciprocal of the dilution of test serum that resulted in
≥50% reduction in average plaques from virus control was recorded as
the PRNT50 value.
2.6. Drug resistance profiling
BDGR-4-resistant viruses were selected by blind passaging VEEV TC-
83 in the presence of the compound 50 nM (Passage 0) and ending at
3200 nM (Passage 7) in six-well plates. Drug concentration was in-
creased by two-fold at each new passage. Cells were infected at an in-
itial MOI of 1 in Eagle's Minimum Essential Medium supplemented with
2% FBS and 5mM L-glutamine (Corning CellGro). At each passage,
three replicates were made for each drug concentration. VEEV TC-83
was also passaged without compound in triplicate. To sequence viruses
at each passage, the supernatant from each passage was harvested and
RNA was isolated using Trizol LS (Invitrogen). A tiling approach was
used to amplify 1 kb fragments of the entire genome which overlapped
each other by 500 bp. cDNA was synthesized from purified RNA using
random hexamer primers and Superscript IV (Thermofisher). cDNA was
amplified through 30 rounds of PCR, using the Phusion High-Fidelity
Kit (Thermofisher F553L) and a set of 25 primer pairs to doubly cover
the whole genome, making PCR fragments either 500 bp or 1 kb in
length. PCR products were purified using the Wizard SV Gel and PCR
Clean-Up System (Promega A9282). Libraries for next-generation se-
quencing were prepared using the Nextera XT kit (Illumina), then se-
quenced on either the Illumina MiSeq or NextSeq 500. Data was ana-
lyzed using CLC Genomics Workbench v.10 (Qiagen). We filtered reads
with a Phred score< 20, mapped reads to the seed stock consensus
sequence, and identified variants that appeared above 1% in all reads at
positions with a coverage of at least 400.
2.7. Mouse studies for Type I IFNs and clinical chemistry profiles
BALB/c mice were injected IP with a 25mg/kg of BDGR-4 BID for 4
days and the expression of Type I IFNs in the brain and serum and a
clinical chemistry panel were measured. To measure IFN, we used the
ProcartaPlex™ multiplexed immunoassay (Affymetrix eBioscience, CA)
according to manufacturer's instructions. Cytokine standards were
prepared to determine the concentration of cytokine in the samples and
the samples were analyzed on a MagPix (Luminex Corp.). Data analysis
was performed using the xPONENT software. A curve fit was applied to
the standards and the sample concentrations extrapolated from the
standard curve using five-parameter logistic method. Clinical chemistry
analysis was performed on the serum using a DiaSys respons® 910 Vet
analyzer (DiaSys Diagnostic Systems, USA, Wixom, MI). Machine was
calibrated, and controls run prior to sample analysis.
2.8. Statistical analyses
P values were generated from comparisons of survival data using
the Log-Rank (Mantel-Cox) test using Prism 6 (Graph Pad Software, Inc)
and compared using the Bonferroni method. P values will be calculated
for each group (K=8). Analyses of each P value generated by the
Mantel-Cox test were evaluated by comparison to a Bonferroni cor-
rected threshold of 0.0125 (p= 0.05) to determine significance.
3. Results and discussion
3.1. Chemical synthesis and in vitro characterization of ML336 analogs,
BDGR-4, BDGR-5, BDGR-69 and BDGR-70
BDGR-4, BDGR-5, BDGR-69, and BDGR-70 (Fig. 1) were synthesized
as described in detail in the Supplemental Information. The inhibitory
activity of each compound was tested in vitro using a cytopathic effect
(CPE) assay and titer reduction assay. Both assays used Vero 76 cells
that were infected with 0.05 MOI of VEEV TC-83. The endpoint of the
CPE assay was taken at 2 days post-infection and the EC50 values re-
present the mean ± standard deviation from more than three in-
dependent experiments of which each experiment was performed with
more than 8-concentrations prepared by two-fold serial dilution. The
titer reduction assays were determined after 18 h of incubation
(Table 1). The standard deviations reflect the testing completed for
several independent syntheses. With ML336 and BDGR-4 in hand, we
regionally diversified the parent structure to assess structure-activity
and structure-property relationships, yielding 30 amidine analogs.
These compounds were prepared to survey structural differences on the
phenyl ring core, the N-amide substituent, and augmentations of the
amidine ring itself. Most of the compounds showed at least a 10-fold
loss in VEEV CPE potency and/or a lackluster demonstration of titer
reduction (< log 5), compared to BDGR-4. Resultantly, BDGR-4, -5, -69
and −70 showed the best overall CPE potency and titer reduction, and
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these were further evaluated for initial physiochemical and ADME de-
termination (Table 1). While ML336 and BDGR-4 were evenly matched
in terms of no discernible mammalian cytotoxicity, potent CPE inhibi-
tion, robust viral titer reduction, reasonable mouse plasma stability and
mouse plasma protein binding, BDGR-4 was> 2.5-fold more soluble
and showed an 11% improvement in microsomal stability solubility
compared to ML336 (Table 1). Given these advancements, BDGR-4,
which featured a 4-methoxyphenyl moiety in place of the ML336 N-
phenyl ring on the amide group, was used as the benzamidine prototype
against which newer benzamidine analogs and other scaffolds were
compared. The 4-methoxyphenyl amide moiety that was deemed ben-
eficial in BDGR-4 was incorporated in BDGR-5; however, a methyl
group was integrated at the C3 position of the 5-nitrophenyl core. Po-
tent antiviral activity in the in vitro viral assays was observed, but
BDGR-5 showed inferior microsomal stability with only 14.6% of the
parent remaining after 1 h of exposure. Enantiomers BDGR-69 and
BDGR-70, prepared to assess the effect of introducing a chiral center at
the alpha-position of the amidine moiety, also offered the possibility of
integrating a potentially beneficial methyl group that might occupy a
similar region of space as the methyl group of BDGR-5. The structural
change was well tolerated in terms of antiviral activity, affording
comparable protection from VEEV CPE with EC50 values= 25–28 nM,
robust reduction in viral titer (log > 7 for both), and gains in micro-
somal stability compared to BDGR-5; however, BDGR-4 outperformed
these analogs in terms of at least a 26% improvement in mouse mi-
crosomal stability. Ultimately, the overall profile of BDGR-4 was shown
to be superior to ML336 and the analogs described here.
3.2. Prophylactic efficacy of BDGR-4 at several doses BID for 5 days in
C3H/HeN mice infected with VEEV TC-83
Based on the in vitro characterization data of the BDGR compounds
(Table 1), BDGR-4 was the first compound chosen to examine efficacy
over a 21-day period. Based on our prior antiviral efficacy studies of
ML336, we chose a range of doses that were higher and lower than the
initial assessment at 5mg/kg/day (Schroeder et al., 2014). The anti-
viral efficacy was measured for BDGR-4 at 1, 5 and 25mg/kg/day;
compound was administered twice daily (BID) at 12 h apart. Groups of
C3H/HeN mice were treated with BDGR-4 or with placebo beginning
2 h prior to VEEV TC-83 challenge and continuing for 5 days. Mice were
monitored for survival, weight loss and viral titer in brain (Fig. 2). The
5mg/kg/day group protected 4/6 mice while the 25mg/kg/day pro-
tected only 2/6 mice (Fig. 2A). This suggested that the dosing and/or
formulation was not optimal. Qualitatively, our ability to formulate
BDGR-4 was better than ML336 as determined by visual inspection
suggesting greater solubility. The recovery of mice by body weight was
similar at 5 and 25mg/kg/day (Fig. 2B). Interestingly, the 25mg/kg/
day reduced viral titers in the brain by approximately two logs better
that then 5mg/kg/day dose (Fig. 2C). Based on the results of this study,
two additional derivatives were chosen for additional testing and eva-
luation in mice.
3.3. Prophylactic efficacy of BDGR-69 and BDGR-70 at 50 mg/kg/day BID
for 5 days in C3H/HeN mice infected with VEEV TC-83
We screened two additional derivatives, BDGR-69 and BDGR-70, in
a mouse efficacy study. Based on the brain titer results observed for
BDGR-4 at 25mg/kg/day (Fig. 2C), we selected a higher dose for
screening (50mg/kg/day) and we also adjusted the formulation slightly
from 21.4%PEG400/8.6%RH40/70%Water to 25%PEG400/10%RH40/
65%Water. This formulation was used in all subsequent animal ex-
periments. Groups of C3H/HeN mice were treated with 25mg/kg/day
BID with BDGR-69 or BDGR-70 or with placebo beginning 2 h prior to
VEEV TC-83 challenge and continuing for 5 days as above. Mice were
monitored for survival and weight loss (Fig. 3). BDGR-69 and 70 pro-
tected 3/6 and 4/6 mice respectively (Fig. 3A). The recovery of mice
that survived challenge was similar for both compounds as determined
by body weight (Fig. 3B).
Fig. 1. Structures of ML336 and related analogs, BDGR-4, BDGR-5, BDGR-69 and BDGR-70.
Table 1







microsomal stabilitye, % parent
after 1 h
plasma stabilityf, % parent
after 3 h
plasma protein bindingf, % bound at
1 μM/10 μM
ML336 32 ± 5 7.0 ± 0.4 40.4 42.9 65.4 85.0/77.0
BDGR-4 47 ± 21 >6.2g 105.6 54.5 66.4 84.3/73.7
BDGR-5 29 ± 6 5.0 ± 1.8 > 41 14.6 ND ND
BDGR-69 28 ± 7 7.2 ± 0.7 > 41 27.7 ND ND
BDGR-70 25 ± 8 7.0 ± 0.6 > 41 25.1 ND ND
a None of these compounds showed mammalian cytotoxicity (CC50 > 50 μM, VERO76 cells).
b cytopathic effect (CPE) assay in VERO76 cells.
c Done at 18 h post infection using 5 μM compound concentration in VERO76 cells.
d Kinetic solubility in 1xPBS buffer.
e Mouse microsomes.
f Mouse plasma.
g No progeny virus plaques were detected. ND=not determined.
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3.4. Prophylactic efficacy of BDGR-4 and BDGR-70 at 5 and 25mg/kg/
day BID for 8 days in C3H/HeN mice infected with VEEV TC-83
Based on the successful partial protection of mice from VEEV TC-83
with BDGR-4 and BDGR-70, we opted to extend dosing through the
period when untreated mice begin to succumb to disease (approxi-
mately day 8); i.e. an additional 3 days. We posited that with an ad-
ditional 3 days we could increase protection and reduce viral brain
titers. Groups of C3H/HeN mice were treated with 5 or 25mg/kg/day
delivered BID with BDGR-4 or BDGR-70 or with placebo beginning 2 h
prior to VEEV TC-83 challenge and continuing for 8 days. Mice were
monitored for survival and weight loss (Fig. 4). BDGR-4 and -70 showed
complete protection of mice at 25mg/kg/day (Fig. 4A). The recovery of
mice that survived challenge was similar for both compounds as de-
termined by body weight (Fig. 4B). While both compounds showed
similar levels of protection, BDGR-4 demonstrated greater solubility
and microsomal stability, and hence this compound was chosen for
subsequent evaluations.
3.5. Prophylactic efficacy of ML336 and BDGR-4 at a single dose in BALB/
c mice infected with 10LD50 of VEEV TrD
Based on the successful protection of mice from VEEV TC-83 with
BDGR-4, we wanted to test its antiviral activity with the wildtype
strain, VEEV TrD. Additionally, we wanted to know how ML336, our
prototype compound, would compare. In our prior mouse efficacy study
with ML336 (Schroeder et al., 2014), significant survival rates (71%)
were observed with VEEV-TC-83 infected mice treated with 5mg/kg/
day of compound (administered twice a day at 2.5mg/kg). Based on
this prior study, we opted for a much higher concentration for this
screen, 12.5mg/kg, twice per day, and the longer 8 days of treatment,
twice per day.
Fig. 2. Prophylactic efficacy of BDGR-4 administered for 5 days in C3H/
HeN mice challenged with intranasal VEEV TC-83. Groups of six C3H/HeN
mice per treatment, vehicle, BDGR-4 at 1, 5 or 25mg/kg/day, were assessed for
(A) survival and (B) morbidity over 21 days following an i.n. challenge with
VEEV TC-83. (C) Brains (n=4) were taken for VEEV TC-83 titer by TCID50 on
day 4. (D) Treatments were administered i.p. in a volume of 0.1 ml in 25%
PEG400/10%RH40/65%water starting at 2 h prior to virus infection (D0) and
were given BID for 5 days (D0-D4).
Fig. 3. Prophylactic efficacy of BDGR-69 and -70 tested in C3H/HeN mice
and challenged intranasally with VEEV TC-83. Groups of six C3H/HeN mice
per treatment, vehicle, BDGR-69 or BDGR-70 at 50mg/kg/day, were assessed
for (A) survival and (B) morbidity over 14 days following a s.c. challenge with
VEEV TC-83. (C) Treatments were administered i.p. in a volume of 0.1 ml in
21.4% PEG400/8.6% RH40/70% water starting at 2 h prior to virus infection
(D0) and were given BID for 5 days (D0-D4).
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Groups of BALB/c mice were treated with 25mg/kg/day with
BDGR-4, ML336, or with placebo beginning 2 h prior to 10LD50 VEEV
TrD challenge by s.c. Treatment was continued for 8 days, BID. Mice
were monitored for survival (Fig. 5) and weight loss (data not shown).
BDGR-4 and ML336 showed 100% protection of the mice challenged
with VEEV TrD (Fig. 5). Based on the results of this study and in
combination with the superior in vitro ADME profile compared to the
analogs discussed herein, BDGR-4 was chosen to move forward for
additional testing and evaluation.
3.6. Prophylactic and therapeutic efficacy of BDGR-4 at a single dose in
BALB/c mice challenged with VEEV
Based on the protection observed of mice at 25mg/kg/day with
BDGR-4 (Fig. 5A) with 8 days of dosing, we tested the therapeutic
potential of compound administration at 24 and 48 hpi. Groups of mice
were treated with 25mg/kg/d of BDGR-4 beginning 2 h before, or 24 or
28 h after virus challenge and continued for 8 days. Mice were mon-
itored for survival (Fig. 6A) and weight loss (Fig. 6B). A cohort of mice
was euthanized on 4 dpi from each group to collect brain tissue for virus
titration (Fig. 6C).
Treatment of mice with BDGR-4 at 25mg/kg/day provided pro-
tection in all groups through day 21 with only a single animal suc-
cumbing to disease on 12 dpi in the 48-h therapeutic group (Fig. 6A).
Weight change tended to increase slowly through 4 dpi. In placebo
treated mice, a sharp decline in weights was observed beginning 1 dpi,
which continued through 7 dpi. The groups of mice prophylactically-
treated and treated 24 hpi with BDGR-4 continued to have similar levels
of weight over time (Fig. 6B). Virus titer in BDGR-4-treated animals
(n= 4 per group) ranged from 2 to 4 logs lower titers as compared to
placebo-treated animals (Fig. 6C).
From these studies we concluded that the level of the dose and the
duration of dosing was optimal for therapeutic treatment when used at
24 hpi at 25 mg/kg/day. Future studies will examine additional dosing
regimen approaches as this series of compounds is advanced for studies
of alternate routes such as the oral and intravenous routes.
3.7. Assessment of Type I IFN induction and clinical chemistry following
four days of BID dosing of BDGR-4
Interferon is a potent inhibitor of New World alphaviruses in vivo
and in vitro (Carpentier and Morrison, 2018; Frolov et al., 2012; Ryman
and Klimstra, 2008), so it was essential that we determine the extent to
which BDGR-4 induced Type-I IFNs. To assess the extent to which
BDGR-4 induced a Type I IFN response, BABL/c mice were dosed with
BDGR-4 or vehicle over the course of 4 days and IFNα and IFNβ levels
were measured in the brain and serum (Table 2). The results demon-
strate that BDGR-4 does not induce either of the Type I IFNs and
therefore the effect of the drug on viral load is not due to the direct
induction of type I IFNs by the drug. This is important since alpha-
viruses are highly sensitive to IFN Type 1. In addition, the results from
clinical chemistry demonstrate that BDGR-4 dosing for 4 days does not
affect the levels of liver or kidney enzymes demonstrating that it is not
toxic for those organs (Table 2).
3.8. In vitro and prophylactic efficacy of BDGR-4 at a single dose in
C57BL/6 mice infected with EEEV
Our goal in development of a New World alphavirus therapeutic is
to identify those small molecules that have the broadest spectrum of
activity against V/E/WEEV. As such we tested BDGR-4 using the pre-
viously mentioned CPE and titer reduction assays against WEEV and
EEEV. The EC50 values of BDGR-4 against WEEV and EEEV were 102
and 149 nM, respectively, with a 6-log titer reduction for WEEV
(Table 3). Given the excellent in vitro antiviral activity, we moved
BDGR-4 forward for testing in a lethal mouse model of EEEV. Because
Fig. 4. Prophylactic efficacy of BDGR-4 and -70 tested in C3H/HeN mice
and challenged intranasally with VEEV TC-83. Groups of six C3H/HeN mice
per treatment, vehicle, BDGR-4 or BDGR-70 at 25mg/kg/day, were assessed for
(A) survival and (B) morbidity over 14 days following a s.c. challenge with
VEEV TC-83. (C) Treatments were administered i.p. in a volume of 0.1 ml in
25% PEG400/10% RH40/65% water starting at 2 h prior to virus infection (D0)
and were given BID through D7.
Fig. 5. Prophylactic efficacy of ML336 and BDGR-4 tested in BALB/c mice
challenged with VEEV TrD. Groups of four BALB/c mice per treatment, ve-
hicle, ML336 or BDGR-4, were assessed for survival over 21 days following a
s.c. challenge with 10LD50 VEEV TrD. ML336 or BDGR-4 were dosed at
12.5 mg/kg BID delivered by i.p. Treatments were administered i.p. in a volume
of 0.1ml in 25% PEG400/10% RH40/65% water starting at 2 h prior to virus
infection (D0) and were given BID through D7.
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of the aggressive disease progression of EEEV in mice, we hypothesized
that we may need a higher concentration of BDGR-4 to achieve sig-
nificant protection. Hence, we doubled the amount administered to 25
mg/k, twice per day.
Groups of mice were treated with 50mg/kg/day of BDGR-4
(n= 10), or with placebo (n=15) beginning 2 h prior to virus or sham-
infected challenge and continuing for 8 days. Treatments were ad-
ministered in a volume of 0.1 ml and were given twice a day at 25mg/
kg. Mice were monitored for survival and weight loss. A cohort of mice
was euthanized on 6 dpi from the select groups to collect brain tissue
for virus titration.
EEEV replicates faster in mice and hence, a higher dose of 50mg/
kg/day (25mg/kg BID) was chosen for this study. Treatment of mice
with BDGR-4 at 50mg/kg/day provided protection through day 21
with only a single animal succumbing to disease on 12 dpi (Fig. 7A).
Weight change tended to increase slowly through 4 dpi. In placebo
treated mice, a sharp decline in weights was observed beginning 5 dpi,
which continued through 7 dpi. Mice treated with BDGR-4 continued to
increase through to 7 dpi (Fig. 7B). Normal controls and placebo-
treated, sham-infected mice increased similarly to animals treated with
compound (Fig. 7B). Virus titer was quantified in brain tissue obtained
from a cohort of animals from select groups on 6 dpi. Virus titer in
BDGR-4-treated animals was significantly reduced as compared with
infection controls and was similar to titers in placebo-treated, sham-
infected animals (Fig. 8A). Lastly, we wanted to determine the im-
munological status of the animals to see if the animals mounted a
neutralizing Ab response to virus infection.
A measurable neutralizing antibody titer was observed in 6 of the 9
mice ranging from 1.5 to 4.5 log10 PRNT 50 (Fig. 8B).
3.9. Concentration-based dynamics of emergence of drug resistance to
BDGR-4
To determine the concentration of BDGR-4 that promotes resistance
to TC-83, we passaged TC 83 in Vero76 cells in the presence of doubling
concentrations of BDGR-4, starting at 50 nM and ending at 3200 nM, for
a total of 7 concentrations. The approach is similar to that used by
others to examine the emergence of mutations as they arise in vitro at
various concentrations (Foll et al., 2014; Renzette et al., 2014). Three
replicates for each concentration were sequenced using the Illumina
NextSeq platform, and the sequences were aligned to the sequence of
Fig. 6. Prophylactic and therapeutic efficacy of BDGR-4 in BALB/c mice challenged with VEEV TrD. Groups of eight BALB/c mice per treatment, vehicle, or
BDGR-4 at 25mg/kg/day, were assessed for (A) survival and (B) morbidity over 24 days following a s.c. challenge with 10LD50 VEEV TrD. (C) Four additional mice
were used to determine the VEEV TrD titer by plaque assay on day 4. (D) All dosing was BID for a total of 8 days and delivered by i.p. with compound formulated in
25%PEG400/10%RH40/65%Water. Prophylactic doses started at 2 h prior to virus challenge and therapeutic doses started at 24 or 48 hpi.
Table 2
Assessment of Type I IFN and clinical chemistry following BDGR-4 dosing.
Analyteb Vehiclea BDGR-4a
IFNα serum (pg/ml) 0 0
IFNα brain (pg/ml) 6 6
IFNβ serum (pg/ml) 0 0
IFN β brain (pg/ml) 0 0
Alkaline Phosphatase (ALP:U/L) 67.1 ± 7.8 62.7 ± 12.8
Alanine Aminotransferase (ALT: U/L) 28.3 ± 8.4 23.0 ± 4.9
Aspartate Aminotransferase (AST:U/L) 141.7 ± 73.4 108 ± 19.1
Blood Urea Nitrogen (BUN:mg/dL) 18.7 ± 1.4 21.0 ± 1.0
Glucose (mg/dL) 156.4 ± 21.1 184.5 ± 26.4
Total Protein (g/dL) 4.4 ± 0.18 4.3 ± 0.2
Calcium (mg/dL) 9.5 ± 0.5 9.4 ± 0.3
a Mice were dosed with vehicle or BDGR4 (25mg/kg BID) by IP injections
over 4 days.
b Type I IFNs were measured in serum and brain homogenates using a
multiplex Immunoassay with a lower limit of detection for IFNα of 2.81 pg/ml
and lower limit of.detection for IFNβ of 3.39 pg/ml. Results are represented as
average ± S.D. n= 4–10 samples.
Table 3










BDGR-4 102.3 ± 37.8 >6.24c 149.5 ± 24 ND
a cytopathic effect (CPE) assay in VERO76 cells.
b done at 18 h post infection using 5 μM compound concentration in
VERO76 cells.
c No progeny virus plaques were detected. ND=not determined.
C.B. Jonsson, et al. Antiviral Research 167 (2019) 25–34
31
the viral stock before variant calling. As shown in Table 4, mutations
did not emerge until 200 nM. Four mutations, G5414A, A5962T,
A6331G, G6617A reached a majority in the population by 3200 nM;
however, only the mutations at 5962 and 6331 resulted in amino acid
changes, both in the nsP4 gene. Interestingly, multiple mutations re-
sulting in the glutamine at position 210 in nsP4 that emerged though
the three replicates were observed; notably, mutations at all positions at
that codon were observed, all of which led to a mutation to a basic
amino acid. Given a high enough concentration of the compound
(32–64-fold greater than the EC50), TC-83 evolved resistance to BDGR-
4. However, the penetrance of these variants never reached 100%. The
greatest proportion of mutants at 3200 nM were at Q210R (61–79%).
Previously, we measured the resistance of VEEV TC-83 to the early
hit compound, CID15997213 (Chung et al., 2014) and ML366
(Schroeder et al., 2014). In these studies, resistant viruses were selected
by passaging VEEV TC-83 at a much higher concentration of compound
and assessed only the passage 8. Specifically, CID15997213 and ML336
concentration was increased by 2.5 μM every other passage starting at
2.5 μM (Passage 0) and ending at 10 μM (Passage 8). Resistant viruses
were plaque-purified and amplified in the presence of the compound at
5 μM, and these were sequenced by the Sanger method. Of the six
plaques sequenced for the CID15997213-resistant VEEV-TC83, five
carried a Y102C mutation and one had D116N within the amino-ter-
minus of the nsP2 protein. In the study of ML336-resistant viruses, the
Y102C mutation and D116N emerged, and a new mutation at Q210K in
the nsP4. In our studies of BDGR-4, we observed a shift from the nsP2
resistance mutations (Y102C, D116N) to viruses with Q210 (K, R, H).
Previously, we did not assess the penetrance of the resistant virus
phenotypes. As stated above, mutants did not reach greater than
61–79% of the population at 3200 nM. Unfortunately, the nsP4 re-
sistant mutations fall under portions of their respective genes that do
not a precise function or enzyme activity (Rubach et al., 2009). Con-
foundingly, the mutations at Y87 and Q210 in nsP4 are conserved re-
sidues throughout all alphaviruses, however, as yet we have not ob-
served antiviral activity against Old World alphaviruses (data not
shown).
4. Conclusions
Several benzamidine analogs of prototype ML336, a benzamidine
anti-VEEV compound, were prepared and assessed for in vitro anti-
VEEV activity, general cytotoxicity, solubility and microsomal stability.
Fig. 7. Prophylactic efficacy of BDGR-4 tested in C57BL/6 mice challenged
with EEEV FL93–939. (A) Survival of C57BL/6 mice infected by s.c. with EEEV
and treated with various doses of BDGR-4. (B) Average percent weight change
of animals treated with BDGR 4 and infected with EEEV. (C) Treatments were
administered i.p. in a volume of 0.1 ml in 25% PEG400/10% RH40/65% water
starting at 2 h prior to virus infection (D0) and were given BID through D7 for a
total of 8 days.
Fig. 8. Virus titers and neutralizing antibody levels from serum of sur-
viving C57BL/6 mice after EEEV challenge of BDGR-4. (A) Viral titers from
brain tissue collected on 6 dpi from mice treated with BDGR-4. (B) Neutralizing
antibody levels from mice sera collected 21 days following EEEV challenge of
BDGR-4 treated mice. Upper and lower dashed lines represent upper and lower
limits of assay detection, respectively. Dashed line represents limit of assay
detection.
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None of the compounds showed mammalian cytotoxicity liability
(CC50 > 50 μM), and data obtained from CPE and titer reduction stu-
dies revealed nanomolar potency and robust attenuation of viral re-
plication for the subset of compounds. Differences in microsomal sta-
bility and solubility differentiated the compounds, highlighting the best
overall profile associated with BDGR-4.
Several of the analogs were tested initially in a lethal mouse model
of VEEV TC-83. The best protection was noted by BDGR-4 and so this
compound was advanced to evaluation in lethal mouse models of the
wild type VEEV TrD and EEEV. In both models, mice survived challenge
when treated with 25mg/kg/day. Therapeutic treatment of mice with
BDGR-4 beginning as late as 48 h after VEEV infection provided 100%
protection. The ability of BDGR-4 to protect mice from encephalitis is
not due to the induction of IFNα or IFNβ as we did not detect either of
these cytokines in the brain or sera of mice treated with the compound.
In addition, there was no increase in liver or kidney enzymes in mice
treated with BDGR-4 in comparison to vehicle treated mice suggesting
that BDGR-4 did not have toxic side effects in mice.
A comprehensive compendium of antivirals against alphaviruses by
Ching et al., (2017) report several inhibitors acting at various stages of
virus replication that are direct-acting or host-targeting (Ching et al.,
2017). Of those reviewed, there were 14 publications of the New World
alphaviruses, however, most of the publications were studies performed
in vitro with most compounds showing micromolar activity (Ching
et al., 2017; Markland et al., 2000). Of these, only three studies to our
knowledge have tested the efficacy of the compounds in mice, and none
showed a substantial improvement in survival of the challenged mice.
In conclusion, the BDGR-4 molecule may represent the first viable lead
for therapeutic development for New World alphaviruses.
Lastly, our viral resistance studies presented herein and previously
published (Chung et al., 2016; Schroeder et al., 2014) suggest that this
compound series directly targets polymerase function. It is known that
nsP1-4 each contribute to viral replication. The first 97 amino acids of
the alphaviruses nsP4 is predicted to have a disordered domain
(Urakova et al., 2017), which may promote interactions with the other
nonstructural proteins, nsP1-3, or host factors. Functional mapping of
the nsP4 suggests residues within the terminal 500 amino acids of nsP4
that function as the finger domain (G159, Q191K, G324) and catalytic
core (conserved GDD motif, 464–466) (Sawicki et al., 1990). The ap-
pearance of resistance mutations in the studies reported here and pre-
viously suggest the compound may lie in an area where nsP2 and nsP4
interact. For example, prior studies with Sindbis virus have reported
interactions between the nsP1 and nsP4 in minus-strand synthesis (Fata
et al., 2002) and nsP2 and nsP4 (Hahn et al., 1989). While we do not
have evidence at this time, the binding of the compound into a struc-
tural pocket of nsP2-4 interactions, would potentially impact minus-
strand synthesis. Current studies are in progress to map the interaction
of ML336 with the nsp2 and 4.
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Glossary
VEEV: Venezuelan equine encephalitis virus
EEEV: Eastern equine encephalitis virus
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